Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Pledges 1 Billion Yen in Global Fund, 2nd Investment in Fighting for HIV, TB, and Malaria
June 4, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
- Rakuten Medical Sets Up Outposts in Netherlands, Taiwan
June 3, 2019
- Janssen Japan Files Erleada for Castration-Sensitive Prostate Cancer
June 3, 2019
- Additional OS Data to Be Added to Xospata’s US Label: Astellas
June 3, 2019
- Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
- Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
May 31, 2019
- Novartis, Sumitomo Dainippon to Jointly Promote Equa, EquMet
May 31, 2019
- Teva Takeda Yakuhin Voluntary Recalls Menatetrenone Capsules
May 31, 2019
- Application for Mitsubishi Tanabe’s ALS Drug Pulled in EU
May 31, 2019
- Ono Files Opdivo for Second-Line Treatment of Esophageal Cancer
May 31, 2019
- Otsuka Shoots for Pharma Sales of 1.08 Trillion Yen in 2023
May 31, 2019
- Tokyo Court Dismisses Genentech’s Bid to Block Rituxan Biosimilar
May 30, 2019
- Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
- Japan’s 1st ADA Deficiency Treatment Revcovi Now Available: Teijin Pharma
May 30, 2019
- Janssen Launches Simponi Autoinjector in Japan, Mitsubishi Tanabe in Charge of Distribution
May 30, 2019
- MSD/Bayer’s Rosuzet Now Available in Japan
May 29, 2019
- Takeda to Launch New Manufacturing Facility for Leuplin; Aims to Maintain Its 110 Billion Yen Sales
May 29, 2019
- Insulin/GLP-1 Receptor Agonist Combo Demonstrates Efficacy in Japan PIII: Sanofi
May 29, 2019
- NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…